DEM BioPharma, Inc. (DEM Bio), a biopharmaceutical company dedicated to discovering novel targets for solid tumors and ...

HMBD-501 is a HER3-targeted ADC with a differentiated mechanism of action, engineered by Hummingbird Bioscience for optimal safety and efficacy ...

Spyre Therapeutics (SYRE) stock analysis: de-risked pipeline, cash runway to H2 2028, and 2026–2027 Phase 2 catalysts in ...

Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...

While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.

M+ cash runway to 2029, bitopertin FDA NDA/accelerated approval catalyst, and DISC-0974 myelofibrosis data—read now.

Webcast to be held Tuesday, January 6th at 8:00 a.m. ETSAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company ...

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a ...

The "Biological Therapies for Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

FibroBiologics submits IND application with US FDA to initiate clinical trials of CYPS317 in psoriasis patients: Houston Saturday, January 3, 2026, 11:00 Hrs [IST] FibroBiologics ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a favorab ...